LB-1901

N/A

Report date: 2024/05/11 20:00:08

Base Information

Drug NameLB-1901
Drug Alias NameAutologous CD4-targeted CAR-TAnti-CD4 chimeric antigen receptor T cell therapyLCAR-T2C CAR-T cellsLB-1901LB1901
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD4Immunologic cytotoxicityT lymphocyte replacements
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, T-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLegend Biotech America
Inactive CompaniesBeijing Gao Boren Hospital Co LtdNanjing Legend Biotechnology Co Ltd
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, T-Cell
Inactive IndicationsLeukemia, T-Cell

Other Information

ATC CodeN/A
Related LinksN/A